ArticleAnimals : an open access journal from MDPI2026
A Novel Recombinant MAGE-B10-HSP110 Fusion Protein Enhances Innate and Adaptive Immune Responses in Mice: A Potential Vaccine Candidate for Canine Mammary Tumors.
Article in Animals : an open access journal from MDPI, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Melanoma-associated antigen (MAGE) is a promising immunotherapeutic target for cancer vaccines. Heat shock protein 110 (HSP110), expressed in various tumors, including canine mammary tumors, serves as a molecular marker. This study aimed to develop a recombinant fusion protein by linking HSP110 with MAGE-B10 to target MAGE-B10-expressed tumors and assess immune response efficacy. The recombinant MAGE-B10-HSP110 (rMAGE-B10-HSP110) fusion protein was constructed, and separate recombinant MAGE-B10 (rMAGE-B10) and recombinant HSP110 (rHSP110) proteins were also prepared for comparison. Our study on mice is distributed across five treatment groups: the rMAGE-B10-HSP110 fusion protein, rMAGE-B10, rHSP110, a protein mixture, and a PBS control. Antibody responses specific to canine MAGE-B10 were measured using ELISA, while splenocyte activation, proliferation, and cytokine production were analyzed using flow cytometry. The results showed significantly higher antibody responses in mice immunized with the rMAGE-B10-HSP110 fusion protein compared to those receiving PBS or rHSP110 on days 7, 14, and 21. The proportion of CD3+ and CD4+ lymphocytes were significantly higher in these mice (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.